UTILIZATION OF TETANUS TOXOID VACCINATION AND ASSOCIATED FACTORS AMONG WOMEN OF REPRODUCTIVE AGE IN LIRA CITY, NORTHERN UGANDA. ACROSS-SECTIONAL STUDY.
DOI:
https://doi.org/10.51168/insights.v1i10.13Keywords:
TT vaccination, Women of reproductive age, Ober HCIVAbstract
Background
Tetanus is a fatal disease caused by Clostridium Tetani. It affects women during pregnancy and 6 weeks postpartum and their neonates in the first 28 days of life who were not protected by the TT vaccine. Africa contributes 44%of global deaths due to tetanus and Uganda with neonatal mortality due to tetanus at 0.65/100000. Tetanus toxoid vaccination is evident in protecting against tetanus disease by receiving 5 doses for lifelong protection.
Methodology
A cross-section study employing the quantitative method of data collection was done among 151 mothers attending ANC at Ober HCIV who were selected through simple random sampling. Data was entered, double-checked, and cleaned using Statistical Package for Social Sciences (SPSS) version 23 for analysis.
Results
The response rate was 100%. The level of TT utilization was 58.3% as 41.7% have never received any dose, TTV1- 25.8%, TTV2- 15.2%, TTV3- 8.6%, TTV4- 6.6% and TTV5-2.6%. However, associated factors included the husband’s education level, Family monthly income, exposure to mass media, partner involvement, number of antenatal visits, Place of delivery, Modern family planning use, time travel to the health facility, access to TTV, TT vaccination outreaches in communities and the level of knowledge on TT vaccination utilization.
Conclusion
Utilization of TT vaccination is very low at 58.5% according to the WHO national target of 90%. Attending antenatal care at least 4 times, having access to TT vaccines, and having good knowledge regarding TT vaccination are significant associations for the utilization of TT vaccination among women of reproductive age group.
Recommendation
Midwives and Nurses should endeavor to sensitize women of reproductive age and their husbands or next of kin about the importance of utilizing and completing vaccination schedules about maternal and neonatal tetanus.
References
Aboagye, R. G., Amu, H., Dowou, R. K., Bansah, P., Oaikhena, I. O., & Bain, L. E. (2023). Prevalence and correlates of tetanus toxoid uptake among women in sub-Saharan Africa: Multilevel analysis of demographic and health survey data. PloS one, 18(12), e0296174.
Amin, M. B., Roy, N., Meem, A. E., Hossain, E., & Aktarujjaman, M. (2022). Trends and determinants of taking tetanus toxoid vaccine among women during last pregnancy in Bangladesh: Country representative survey from 2006 to 2019. PloS one, 17(10), e0276417.
Anatea, M. D., Mekonnen, T. H., & Dachew, B. A. (2018). Determinants and perceptions of the utilization of tetanus toxoid immunization among reproductive-age women in Dukem Town, Eastern Ethiopia: a community-based cross-sectional study. BMC international health and human rights, 18, 1-10.
Asmamaw, D. B., Debebe Negash, W., Aragaw, F. M., Eshetu, H. B., Asratie, M. H., & Belachew, T. B. (2023). Spatial distribution and associated factors of poor tetanus toxoid immunization among pregnant women in Ethiopia: spatial and multilevel analysis. Frontiers in Global Women's Health, 4, 1138579.
Belay, A. T., Fenta, S. M., Agegn, S. B., & Muluneh, M. W. (2022). Prevalence and risk factors associated with rural women’s protection against tetanus in East Africa: evidence from demographic and health surveys of ten East African countries. PloS one, 17(3), e0265906.
Dağdeviren, G., Örgül, G., Yücel, A., & Şahin, D. (2020). Tetanus vaccine during pregnancy: data of a tertiary hospital in Turkey. Turkish journal of medical sciences, 50(8), 1903-1908.
Dubale Mamoro, M., & Kelbiso Hanfore, L. (2018). Tetanus toxoid immunization status and associated factors among mothers in Damboya Woreda, Kembata Tembaro zone, SNNP, Ethiopia. Journal of nutrition and metabolism, 2018.
Gebremedhin, T. S., Welay, F. T., Mengesha, M. B., Assefa, N. E., & Werid, W. M. (2020). Tetanus toxoid vaccination uptake and associated factors among mothers who gave birth in the last 12 months in Errer District, Somali Regional State, Eastern Ethiopia. BioMed Research International, 2020.
Gelaw, T., Ayalew, S., & Eyene, K. (2022). Knowledge and Uptake of Tetanus Toxoid Vaccine and Associated Factors Among Reproductive Age Group Women in Hayk Town South Wollo, Ethiopia, Cross-Sectional Study. medRxiv, 2022.2012. 2020.22283731.
Gessesse, D. N., Yismaw, A. E., Yismaw, Y. E., & Workneh, T. W. (2021). Coverage and determinants of protective dose tetanus toxoid vaccine among postnatal women delivered at the University of Gondar Comprehensive Specialized Hospital, northwest Ethiopia, 2019. Clinical Epidemiology and Global Health, 12, 100814.
Ibrahim, Z. A., Sabahelzain, M. M., Elhadi, Y. A. M., Malande, O. O., & Babiker, S. (2023). Predictors of tetanus vaccine uptake among pregnant women in Khartoum state, Sudan: a hospital-based cross-sectional study. Vaccines, 11(7), 1268.
Kajungu, D., Muhoozi, M., Stark, J., Weibel, D., & Sturkenboom, M. C. (2020). Vaccines safety and maternal knowledge for enhanced maternal immunization acceptability in rural Uganda: A qualitative study approach. PloS one, 15(12), e0243834.
Kazibwe, A., Okiror, N. E., Bongomin, F., Namiiro, A. M., Baluku, J. B., Kalyesubula, R., . . . Andia-Biraro, I. (2022). Tetanus in Uganda: clinical outcomes of adult patients hospitalized at a tertiary health facility between 2011 and 2020. Paper presented at the Open Forum Infectious Diseases.
Leo, C. L., Sinaga, M., & Wijaya, R. P. C. (2023). Factors Associated with the Utilization of Tetanus Toxoid Immunization Services among Pregnant Women in Oepoi Health Center, Kupang, East Nusa Tenggara. Journal of Health Promotion and Behavior, 8(1), 58-64.
M Gembe, T Wonyeseleh & W Gezimu. (2024). Protective doses of tetanus toxoid immunization and its associated factors among mothers in southern Ethiopia. 2320501
Mohamed, S. O. O., & Ahmed, E. M. (2022). Prevalence and determinants of antenatal tetanus vaccination in Sudan: a cross-sectional analysis of the Multiple Indicator Cluster Survey. Tropical Medicine and Health, 50, 1-6.
Mugagga, N., Bagaya, B. S., Nantongo, M., Muwanda, F., Mukunya, D., Musaba, M. W., . . . Sekikubo, M. (2023). Antitetanus toxoid antibodies in mothers and neonates: a single-center study from Uganda. BMJ Paediatrics Open, 7(1).
Nalubega, P., Karafillakis, E., Atuhaire, L., Akite, P., Zalwango, F., Chantler, T., . . . Le Doare, K. (2021). Maternal vaccination in Uganda: exploring pregnant women, community leaders, and healthcare workers’ perceptions. Vaccines, 9(6), 552.
Nigussie, J., Girma, B., Molla, A., & Mareg, M. (2021). Tetanus toxoid vaccination coverage and associated factors among childbearing women in Ethiopia: a systematic review and meta-analysis. BioMed Research International, 2021.
Njuguna, H. N. (2020). Progress toward maternal and neonatal tetanus elimination—worldwide, 2000–2018. MMWR. Morbidity and Mortality Weekly Report, 69.
Rabadi, T., & Brady, M. F. (2023). Tetanus toxoid StatPearls [Internet]: StatPearls Publishing.
Shafiq, Y., Khowaja, A. R., Yousafzai, M. T., Ali, S. A., Zaidi, A., & Saleem, A. F. (2017). Knowledge, attitudes, and practices related to tetanus toxoid vaccination in women of childbearing age: A cross-sectional study in peri-urban settlements of Karachi, Pakistan. Journal of infection prevention, 18(5), 232-241.
Tungaraza, M. B., & Moshi, F. V. (2020). Predictors for uptake of tetanus toxoid vaccination during pregnancy among women of reproductive age in Tanzania; An analysis of data from the 2015-16 Tanzania Demographic and Health Survey and Malaria Indicators Survey.
WHO. (2023). Tetanus.
Yaya, S., Kota, K., Buh, A., & Bishwajit, G. (2020). Prevalence and predictors of taking tetanus toxoid vaccine in pregnancy: a cross-sectional study of 8,722 women in Sierra Leone. BMC Public Health, 20, 1-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mathias Turyagumanawe, Christine Joy Abeja, Julius Kayizzi, Derick Modi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
